Future clinical trials should investigate whether expression of VEGF or VEGFR2 in tumour biopsies from patients receiving VEGFR2 kinase inhibitors can be used as diagnostic markers for VEGF-targeted therapies. The gene discussed is KDR; the disease is neoplasm.